We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Obtains FDA Emergency Use Authorization

By HospiMedica International staff writers
Posted on 05 May 2020
BioMérieux’s (Marcy-l'Étoile, France) subsidiary, BioFire Diagnostics, has received Emergency Use Authorization by the US Food and Drug Administration for the BIOFIRE RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2.

The inclusion of SARS-CoV-2 in the BIOFIRE RP2.1 panel allows healthcare providers to quickly identify patients with common respiratory pathogens, as well as those with COVID-19, using one simple test. More...
The BIOFIRE RP2.1 panel takes approximately 45 minutes and tests nasopharyngeal swab samples in transport media. It runs on the fully automated FILMARRAY 2.0 and FILMARRAY TORCH systems and is extremely easy to use.

BioMérieux is currently scaling up supply of the BIOFIRE RP2.1 panel and has made the test kits available for commercial distribution in the USA under EUA as well as internationally where regulatory approval allows. Given the high demand for COVID-19 testing, BioMérieux expects to steadily build inventory levels to address the needs of the thousands of labs and healthcare professionals using one of the nearly 12,000 FILMARRAY systems worldwide.

The BIOFIRE RP2.1 test is the third molecular test from BioMérieux in response to the COVID-19 pandemic, following the launch of the ARGENE SARS-CoV-2 R-GENE test and the BIOFIRE COVID-19 test by the company in March. BioMérieux plans to submit the BIOFIRE RP2.1 panel for FDA de novo clearance. Outside of the US, BioMérieux is simultaneously pursuing CE Mark certification for the BIOFIRE Respiratory 2.1plus (RP2.1plus) panel, which also includes detection of MERS-CoV, on an accelerated timeline. The company has highlighted the need for BioFire’s syndromic approach by pointing out that emerging data suggest patients with COVID-19 may frequently be co-infected with other viruses and/or bacteria.

“The BIOFIRE RP2.1 panel represents our syndromic solution to this unprecedented COVID-19 pandemic. BioFire is dedicated to responding to a rapidly-evolving global epidemiological landscape with urgency and accuracy and this illustrates our contribution to BioMérieux’s public health mission,” said Andrea Kendell, ad interim CEO at BioFire Diagnostics. We believe the syndromic BIOFIRE RP2.1 panel will play a key role now and in the upcoming respiratory season as healthcare providers and patients will likely face the regular group of respiratory pathogens as well as SARS-CoV-2”.

Related Links:
BioMérieux


New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The device combines a minimally invasive, long‑lifetime “read/write” brain‑computer interface (BCI) with assistive devices and AI-driven support (photo courtesy of Epia Neuro)

Implantable Brain-Computer Interface Supports Stroke Recovery and Assistive Function

Stroke leaves many survivors with chronic motor deficits that limit independence, and cognitive decline is a growing concern in aging populations. Stroke is a leading cause of long-term disability in the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.